Karyopharm Therapeutics (KPTI) PT Lowered to $8 at RBC Capital
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $1.81 -10.4%
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
11 Buy, 6 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $8.00 (from $12.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
- Central Retail Corp PCL (CRC:TB) PT Lowered to THB9,000 at Macquarie
- E Ink Holdings Inc (8069:TT) PT Lowered to NT$200 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
